Buy Melanotan II 10mg

Melanotan II (MT-II) is a cyclic analog of the melanocyte-stimulating hormone α-MSH, synthesized at the University of Arizona as part of a research program aimed at developing sunless tanning agents. The cyclic lactam structure — formed by an internal disulfide-like bridge between the N-terminal and C-terminal cysteine-like modifications — provides substantially greater metabolic stability than linear α-MSH, with a plasma half-life several hundred-fold longer than the native hormone. MT-II is a non-selective melanocortin receptor agonist with significant affinity for MC1R, MC3R, MC4R, and MC5R — a receptor binding profile that explains both its desired photoprotective and tanning effects and its unintended libido and erectogenic side effects, which ultimately drove the development of PT-141 as a more targeted derivative. Tanning via MT-II occurs through MC1R activation on melanocytes, the pigment-producing cells of the skin epidermis. When MC1R is activated by α-MSH or MT-II, cAMP levels increase via Gαs-adenylyl cyclase coupling, activating PKA and the downstream transcription factor MITF (microphthalmia-associated transcription factor). MITF drives expression of the melanogenic enzyme cascade: tyrosinase, TRP-1, and TRP-2, which together convert tyrosine to DOPA to dopaquinone and ultimately to eumelanin — the photoprotective black-brown pigment that absorbs UV radiation and reduces UV-induced DNA damage. MT-II promotes eumelanin over phaeomelanin, the reddish-yellow pigment associated with sun sensitivity, making the resulting tan qualitatively different from and more photoprotective than sun-induced tanning in individuals with naturally low MC1R activity. The libido and erectile function effects of MT-II occur primarily through MC4R (and secondarily MC3R) activation in the hypothalamus and spinal cord. Hypothalamic MC4R signaling activates oxytocin release in the paraventricular nucleus and modulates dopaminergic activity in the mesolimbic system, increasing sexual arousal through both central and peripheral mechanisms. In the spinal cord, melanocortin signaling at the lumbosacral level promotes penile erection via nitric oxide release — a pathway that operates independently of the phosphodiesterase-5 (PDE5) mechanism targeted by sildenafil. This dual CNS/spinal mechanism of action means MT-II can produce erections in individuals who are non-responsive to PDE5 inhibitors, including those with neurogenic erectile dysfunction. MC5R activation contributes to sebaceous gland secretion and exocrine function effects, while MC3R involvement connects MT-II to energy balance regulation (MC3R is a major regulator of adiposity and feeding behavior). These additional receptor interactions mean MT-II administration affects a broader physiological territory than its common use cases of tanning and sexual function would suggest, contributing to side effects such as nausea (mediated by area postrema melanocortin receptors) and spontaneous erections (mediated by spinal MC4R/MC3R signaling) that often occur unexpectedly and inconveniently.

Melanotan II is not approved for human use in any country and is sold exclusively as a research peptide. Given this regulatory status, sourcing is critically important: the market contains numerous counterfeit or mislabeled products. HPLC purity ≥98% with mass spectrometry confirmation of the cyclic lactam structure (MW 1024.2 g/mol) is the minimum standard. Given MT-II's capacity to darken pigmented lesions, purity verification is not merely an efficacy concern but a safety one — impure products with unknown contaminants in the context of potential melanocyte stimulation represent a genuinely elevated risk. Dosing protocols commonly reported range from 0.25 mg to 1 mg subcutaneously per session, typically starting at the lowest effective dose (0.25 mg) to assess tolerance and gradually titrating upward. The tanning effect is established over a loading period of daily or every-other-day injections for 1–3 weeks, after which a maintenance dose of 1–2 times per week sustains the tan. Front-loading with nausea prevention (antihistamines or antiemetics) is strongly recommended for first administrations. The melanoma risk associated with MC1R-mediated nevi darkening is the most critical safety consideration and warrants baseline dermatological evaluation before any MT-II use. Individuals with multiple atypical nevi, family history of melanoma, or fair skin type IV–VI (paradoxically, the individuals most likely to be seeking a tan) are at heightened theoretical risk. Any user who notices a changing mole during MT-II use should immediately discontinue and seek dermatological evaluation.

The melanocortin analog landscape is defined by receptor selectivity. Melanotan II binds MC1R, MC3R, MC4R, and MC5R — giving it tanning, libido, appetite, and exocrine effects simultaneously. Melanotan I (Afamelanotide) is a linear MT-II analog that is selective for MC1R, delivering tanning and photoprotection without MC4R-mediated libido/erection effects, nausea, or appetite suppression. For individuals seeking photoprotection or a cosmetic tan without the sexual side effects, Melanotan I is the clearly preferable choice — particularly since it is FDA-approved as Scenesse for EPP, providing a regulatory quality standard. PT-141 (Bremelanotide), by contrast, targets MC4R and MC3R with minimal MC1R activity: it produces the sexual arousal and erectile effects of MT-II without tanning. In terms of safety profile, Melanotan I's selective MC1R agonism makes it substantially safer than MT-II: the nevi-darkening risk is similar (both activate MC1R on melanocytes), but the absence of MC4R-mediated cardiovascular and autonomic effects reduces blood pressure concerns. For users whose primary interest is sexual function, PT-141 is the appropriate choice and has the advantage of FDA approval with characterized clinical safety data. Melanotan II's non-selective profile makes it essentially a predecessor compound that has been superseded by more targeted analogs for most specific applications.